Currently, there are 290.26M common shares owned by the public and among those 285.69M shares have been available to trade.
The company’s stock has a 5-day price change of -9.44% and -37.77% over the past three months. OCGN shares are trading -16.51% year to date (YTD), with the 12-month market performance up to 29.23% higher. It has a 12-month low price of $0.55 and touched a high of $2.11 over the same period. OCGN has an average intraday trading volume of 4.64 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -8.28%, -16.15%, and -43.44% respectively.
Institutional ownership of Ocugen Inc (NASDAQ: OCGN) shares accounts for 25.05% of the company’s 290.26M shares outstanding.
It has a market capitalization of $195.55M and a beta (3y monthly) value of 3.87. The earnings-per-share (ttm) stands at -$0.18. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.47% over the week and 6.60% over the month.
Analysts forecast that Ocugen Inc (OCGN) will achieve an EPS of -0.06 for the current quarter, -0.06 for the next quarter and -0.27 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.06 while analysts give the company a high EPS estimate of -0.06. Comparatively, EPS for the current quarter was -0.03 a year ago. Earnings per share for the fiscal year are expected to increase by 22.12%, and -25.93% over the next financial year. EPS should shrink at an annualized rate of 6.14% over the next five years, compared to 41.20% over the past 5-year period.
Looking at the support for the OCGN, a number of firms have released research notes about the stock. Maxim Group stated their Buy rating for the stock in a research note on October 15, 2024, with the firm’s price target at $4. Chardan Capital Markets coverage for the Ocugen Inc (OCGN) stock in a research note released on March 01, 2023 offered a Buy rating with a price target of $3.50. Mizuho was of a view on August 23, 2022 that the stock is Buy, while ROTH Capital gave the stock Buy rating on June 15, 2022, issuing a price target of $8. Cantor Fitzgerald on their part issued Overweight rating on June 02, 2022.
